Associations of obesity with antidiabetic medication use after living kidney donation: An analysis of linked national registry and pharmacy fill records by Lentine, Krista L. et al.
Clinical Transplantation. 2019;33:e13696.	 clinicaltransplantation.com	 	 | 	1 of 10
https://doi.org/10.1111/ctr.13696
© 2019 John Wiley & Sons A/S. 
Published by John Wiley & Sons Ltd
 
Received:	27	March	2019  |  Revised:	23	July	2019  |  Accepted:	5	August	2019
DOI: 10.1111/ctr.13696  
O R I G I N A L  A R T I C L E
Associations of obesity with antidiabetic medication use after 
living kidney donation: An analysis of linked national registry 
and pharmacy fill records
Krista L. Lentine1  |   Farrukh M. Koraishy1 |   Nagaraju Sarabu2  |   Abhijit S. Naik3  |   
Ngan N. Lam4 |   Amit X. Garg5 |   David Axelrod6  |   Zidong Zhang1  |   Gregory 
P. Hess7  |   Bertram L. Kasiske8 |   Dorry L. Segev9 |   Macey L. Henderson9  |    

















































post‐donation	 anniversary	 (n	 =	 19	 528),	 compared	with	 stable	BMI,	 BMI	 increase	
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1  | INTRODUC TION
Medical	 evaluation	 of	 living	 kidney	 donor	 candidates	 focuses	 on	







hypertensive	 (later	 vs	 early	 incidence	 rate	 ratios,	 7.7	 and	 2.6,	 re‐
spectively).2	 In	a	single‐center	study	of	3956	predominantly	white	
living	donors,	 25%	of	ESRD	events	with	 known	causes	 (n	=	6/25)	
were	related	to	diabetes.3	While	pre‐donation	diabetes	 is	typically	
considered	 an	 exclusion	 for	 donation	 (mandated	 in	 current	Organ	
Procurement	and	Transplantation	Network	[OPTN]	policy),4	risk	fac‐
tors	 for	 post‐donation	 diabetes	mellitus	 (PDDM),	 and	 implications	
for	donor	counseling	and	selection,	are	not	well	defined.
Obesity	 is	 a	 well‐established	 risk	 factor	 for	 diabetes	 and	 for	
chronic	kidney	disease	and	ESRD	in	the	general	population,5,6	but	the	















ical	 practice.	 Prior	 guidelines	 for	 the	 evaluation	 and	 care	 of	 living	
kidney	donor	candidates	recommend	BMI	>35	kg/m2	as	an	absolute	
or	relative	contraindication	to	donation,10‐16	while	other	guidelines	






demographic and health profile in relation to the transplant pro‐
gram's	 acceptable	 risk	 threshold.1 In the context of the national 
obesity	 epidemic,	 overweight,	 and	obese	donors	 now	account	 for	
















and other demographic and clinical factors.
2  | MATERIAL S AND METHODS
2.1 | Data sources
We	conducted	a	retrospective	cohort	study	using	linked	healthcare	














tiple	 sources	 including	data	 clearinghouses,	 retail	 pharmacies,	 and	






tient	 identifiers	 (last	 name,	 first	 name,	 sex,	 date	 of	 birth,	 and	 ZIP	
code	 of	 residence)	were	 transformed	 before	 delivery	 to	 the	 Saint	
Louis	University	researchers	with	Health	Information	Portability	and	
Accountability	 Act	 and	 HITECH‐certified	 encryption	 technology.	
K E Y W O R D S
antidiabetic	medications,	diabetes	mellitus,	health	outcome,	living	donation,	pharmacy	claims,	
registries











time	of	donation	 included:	age,	sex,	 race,	donor‐recipient	 relation‐
ship,	 health	 insurance	 status,	 BMI,	 physical	 limitations,	 education	
level,	employment	 status,	history	of	 smoking,	pre‐donation	hyper‐











Data	 management	 and	 analyses	 were	 performed	 with	 Statistical	
Analysis	Software	(SAS)	for	Windows,	version	9.3	(SAS	Institute	Inc).	






estimated	 the	cumulative	 incidence	of	 insulin	use	and	use	of	each	

























3.1 | Association of obesity with ADM use
The	incidence	of	ADM	use	at	9	years	rose	in	a	graded	manner	with	
higher	BMI:	 underweight,	 0.9%;	 normal	weight,	 2.1%;	 overweight,	
3.5%;	 obese,	 8.5%	 (Figure	 1).	 Compared	with	 donors	with	 normal	
BMI,	 after	 adjustment	 for	 age,	 sex,	 and	 race,	 overweight	 donors	
were	two	times	more	likely	to	fill	ADM	(aHR,	1.632.243.07),	and	obese	







other	 significant	 correlates	 of	 ADM	 included	 female	 sex	 (aHR,	
1.662.172.83)	and	more	recent	years	of	donation	(Table	2).	Compared	
with	 donations	 in	 2007‐2010,	 donations	 in	 2014‐2016	 were	 as‐
















(aHR,	 2.428.3228.61)	 (Figure	4).	Obesity	 at	 donation	was	not	 signifi‐
cantly	associated	with	use	of	insulin	or	glitazones,	which	were	both	
filled	infrequently	(<0.6%	and	no	fill	at	9	years).
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TA B L E  1  Distribution	of	clinical	factors	in	the	study	sample	of	living	kidney	donors	according	to	body	mass	index	(BMI)	at	donation






(n = 11 836)
>30
(n = 6557)
(%) (%) (%) (%)
Donor characteristics
Age	(y) †  ‡  ‡ 
18‐30 31.8 20.7 15.4 16.3
31‐44 29.1 34.6 35.5 39.5
45‐59 31.3 36.4 39.9 37.8
>60 7.8 8.3 9.1 6.5
Female 82.5*  77.2 60.7‡  63.1‡ 
Race *  ‡  ‡ 
White 79.5 77.4 73.4 68.4
Black 7.5 7.8 10.5 15.2
Hispanic 5.2 9.5 12.7 14.2
Other 7.8 5.2 3.4 2.2
Donor/recipient relationship *  ‡ 
Related	recipient	with	diabetes 12.3 11.1 12.3 14.4
Related	recipient	without	diabetes 33.2 34.3 33.2 32.6
Unrelated 54.5 54.7 54.4 53.0
Highest	level	of	education ‡  ‡ 
College	and	Higher 69.4 70.4 68.0 62.7
Grade/High	School 20.5 22.3 24.5 29.2
Unknown 76.5 80.2 7.5 8.1
Employment	status ‡  ‡ 
Working 76.5 80.2 83.0 83.3
Not	working 20.5 17.3 15.0 14.4
Unknown 3.0 2.5 2.0 2.3
Insurance	status *  ‡ 
Insured 71.3 80.1 80.3 76.8
Uninsured 14.9 9.5 9.1 10.6
Unknown 13.8 10.4 10.6 12.6
Hypertension	history 5.6 7.4 12.2‡  14.5‡ 




≥90 74.0 68.2 65.7 66.7
60	to	<90 24.2 29.5 32.2 31.1
<60 1.1 1.5 1.6 1.7
Unknown 0.7 0.7 0.5 0.6
Nephrectomy	type
Open 2.6 4.1 4.0 4.0
Laparoscopic/Unknown 97.4 95.9 96.0 96.0
Year of donation *  * 
2007‐2010 36.9 33.0 32.0 32.3
2011‐2013 37.7 37.3 38.0 38.1
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Pharmacy	 claims	 can	 provide	 efficient,	 non‐obtrusive	 surrogate	
measures	 of	 treated	 clinical	 conditions	 that	 can	 help	 advance	 un‐
derstanding	of	health	outcomes	in	living	donors,	an	important	popu‐
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<18.5 0.63	(0.09‐4.52) 0.67	(0.09‐4.85) N/A
18.5	to	<25 Reference Reference Reference
25	to	<30 2.23	(1.62‐3.06)‡  2.40	(1.74‐3.33)‡  0.79	(0.28‐2.22)
>30 4.59	(3.36‐6.27)‡  4.91	(3.56‐6.77)‡  1.44	(0.53‐3.92)
Age	(y)
18‐30 1.18	(0.86‐1.60) 1.16	(0.85‐1.58) 1.68	(0.55‐5.10)
31‐44 Reference Reference Reference
45‐59 0.80	(0.61‐1.04) 0.79	(0.61‐1.04) 1.03	(0.38‐2.81)
>60 0.92	(0.59‐1.45) 0.96	(0.61‐1.51) N/A
Female 2.17	(1.66‐2.83)‡  2.23	(1.70‐2.93)‡  0.59	(0.26‐1.34)
Race
White Reference Reference Reference
Black 1.26	(0.92‐1.73) 1.26	(0.91‐1.73) 3.48	(1.26‐9.63)* 
Hispanic 1.29	(0.95‐1.77) 1.27	(0.92‐1.75) 2.91	(1.05‐8.12)* 
Other 1.73	(1.04‐2.89)*  1.79	(1.07‐2.99)*  N/A
Donor/recipient relationship
Related	recipient	with	diabetes 1.13	(0.83‐1.54) 1.10	(0.80‐1.51) 1.46	(0.49‐4.38)
Related	recipient	without	diabetes Reference Reference Reference
Unrelated 0.89	(0.70‐1.13) 0.88	(0.69‐1.12) 1.03	(0.42‐2.52)
Highest	level	of	education
College	&	Higher 0.99	(0.77‐1.27) 1.04	(0.81‐1.33) 0.44	(0.19‐1.04)
Grade/High	School Reference Reference Reference
Unknown 1.01	(0.67‐1.52) 1.06	(0.70‐1.60) 0.97	(0.26‐3.61)
Employment	status
Working 1.02	(0.78‐1.36) 1.02	(0.77‐1.36) 0.75	(0.27‐2.05)
Not	Working Reference Reference Reference
Unknown 1.01	(0.67‐1.52) 1.06	(0.70‐1.60) 0.97	(0.26‐3.61)
Insurance	status
Insured Reference Reference Reference
Uninsured 0.93	(0.64‐1.33) 0.96	(0.67‐1.38) 0.22	(0.03‐1.68)
Unknown 0.74	(0.53‐1.04) 0.76	(0.55‐1.07) 0.28	(0.06‐1.27)
Hypertension	history 1.26	(0.74,	2.14) 1.41	(0.86,	2.33) 5.36	(1.49,	19.26)* 
Smoking	history 1.03	(0.81‐1.31) 1.03	(0.81‐1.32) 1.10	(0.45‐2.69)
eGFR	at	donation	(mL/min	per	1.73	m2)
<60 1.64	(0.86‐3.13) 1.75	(0.94‐3.25) 1.77	(0.22‐13.94)
60	to	<90 1.04	(0.81‐1.34) 1.02	(0.80‐1.31) 0.80	(0.30‐2.12)
≥90 Reference Reference Reference
Nephrectomy	type
Open 0.87	(0.52‐1.47) 0.89	(0.53‐1.50) N/A
Laparoscopic/unknown Reference Reference Reference
Year of donation
2007‐2010 Reference Reference Reference
2011‐2013 1.41	(1.08‐1.86)*  1.45	(1.10‐1.91)*  0.49	(0.17‐1.46)
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found	PDDM	rates	by	the	end	of	follow‐up	in	12%	vs	6%	of	donors	










The	 racial	 disparity	 in	 obesity	 observed	 in	 our	 study	 sample	 is	
present	in	the	general	population	and	was	previously	reported	among	



















F I G U R E  2   Incidence	of	antidiabetic	
medication	use	according	to	year	of	
donation
F I G U R E  3  Distribution	of	antidiabetic	
medication	categories	filled	by	9	y	post‐
donation,	according	to	body	mass	index	at	
donation. Medication categories are not 
mutually	exclusive





































dications	other	 than	 type	2	diabetes	 (such	as	off‐label,	use	or	un‐
common	treatment	of	polycystic	ovarian	syndrome)	type	2	diabetes	
is	the	primary	prescribing	indication	for	metformin.
While	ongoing	work	 is	needed,	our	study	has	 implications	 for	
living	 donor	 care.	 Given	 the	 recently	 identified	 associations	 of	
obesity	with	post‐donation	ESRD,2	 obesity	 should	be	 considered	
a	renal	risk	factor	in	donors,	and	of	particular	importance	because	
of	potential	modifiability.	Lifestyle	factors	that	contribute	to	obe‐
sity	 include	 low	 physical	 activity,	 high	 caloric	 intake,	 and	 poor	
sleep	quality.38	Interventional	data	among	donors	are	lacking,	but	
previous	studies	have	shown	that	weight	loss	among	obese	adults	
















terventions and monitored exercise programs in donors are needed 
to	advance	effective	care,	donor	candidates	should	be	counseled	
on	lifestyle	interventions	to	support	achievement	and	maintenance	
of	healthy	body	weight,	 and	 regular	 exercise	 according	 to	 guide‐
lines	for	the	general	population.1	Importantly,	these	interventions	
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should	be	initiated	before	donation	and	maintained	lifelong,	includ‐
ing	as	part	of	annual	post‐donation	follow‐up.1
There	 are	 several	 strengths	 to	 our	 study.	We	 used	 pharmacy	
claims	 as	 a	 measure	 of	 diabetes,	 a	 non‐obtrusive	 surrogate	 that	
avoids	recall	bias	associated	with	survey	studies,	and	complements	
information	acquired	though	other	study	designs.	Using	 this	 large,	



























risk	 factors.	We	 lacked	 information	on	BMI	changes	 for	 the	entire	
follow‐up	period.	However,	 in	 a	 subset	with	BMI	data	 available	 at	
1‐year	 anniversary,	we	 found	 that	BMI	 increase	 is	 associated	with	
subsequent	ADM	use,	independent	of	BMI	at	donation.
In	 conclusion,	 linkage	 of	 national	 US	 donor	 registry	 data	with	
pharmacy	fill	records	demonstrates	that	being	overweight	or	obese	
at	 the	 time	 of	 living	 kidney	 donation	 is	 strongly	 associated	 with	
ADM	use	after	donation.	In	addition,	the	risk	of	ADM	use	appeared	






profile,	 and	 impact	 on	 renal	 and	 cardiovascular	 outcomes	 among	
living	 donors.	 All	 stakeholders—including	 patients,	 primary	 physi‐
cians,	 transplant	 programs,	 policy	makers,	 insurers,	 and	 research‐
ers—should	recognize	the	importance	of	obesity	as	a	contributor	to	
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